Meeting
2022 ASCO Annual Meeting
177Lu-DOTA-TLX591 safety, biodistribution and dosimetry study (ProstACT-SELECT).
Authors
Paola Antonini
Telix Pharmaceuticals, North Melbourne, Australia
Paola Antonini , Danielle Meyrick , Colin Hayward
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT04786847
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS5109)
DOI
10.1200/JCO.2022.40.16_suppl.TPS5109
Abstract #
TPS5109
Poster Bd #
284a
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Safety, tolerability, and dosimetry of 177Lu-TLX591 with best standard of care in patients with PSMA-expressing metastatic castration-resistant prostate cancer (ProstAct-SELECT).
First Author: Nat Lenzo
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.
First Author: William Kevin Kelly
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).
First Author: Scott T. Tagawa
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Susan F. Slovin